Search Results - mark+rubinstein

1 Results Sort By:
Method of Enhanced Adoptive Cellular Therapy without Lymphodepletion
Technology: Lymphodepleting chemotherapy is a significant hurdle to the use of adoptive cellular therapy. MUSC researchers have found a method to overcome the need to provide lymphodepleting chemotherapy to patients receiving Adoptive Cellular Therapy (ACT) by endowing donor T cells with elevated levels of cytokine receptors to outcompete host cells...
Published: 11/13/2015   |   Inventor(s): Mark Rubinstein, David Cole
Keywords(s):  
Category(s): Therapeutic
© 2021. All Rights Reserved. Powered by Inteum